eToro Group Ltd.
ETOR Nasdaq Security Brokers, Dealers & Flotation Companies Financials FY2023–FY2025
Last close · Oct 23, 2026
$23.92
1.6%What eToro Group Ltd. does
No business description yet.
- Legal name
- eToro Group Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 2, 2026
- Accession · CIK
- 0001213900-26-022034
0001493318
Revenue and margins
eToro Group Ltd. had $13.8B of revenue in fiscal 2025, up 9.5% on the year before.
Net income and earnings per share
From fiscal 2023 to 2025, diluted EPS grew 255.1% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $313M in fiscal 2025, 2.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
eToro Group Ltd. returned — to shareholders in fiscal 2025. The diluted share count rose 11.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably eToro Group Ltd. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $388M | $575M | $1.1B |
| Current ratio | — | 3.5x | 4.9x |
| Quick ratio | — | 3.5x | 4.9x |
| Total assets | — | $1.2B | $1.8B |
| Total liabilities | — | −$13.1B | −$14.3B |
| Shareholders' equity | $598M | $14.3B | $16.1B |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ |
| Return on assets rose | — | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | ✓ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | ✓ | ✕ |
| Revenue rose relative to assets | — | — | ✕ |
| F-score | — / 3 | — / 5 | 4 / 8 |
| Accruals ratio | — | −6.4% | −6.9% |
| Altman Z'' | — | — | — |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $3.9B | $12.6B | $13.8B |
| Gross profit | $27.7M | $246M | $253M |
| Research and development | $129M | $131M | $151M |
| Interest expense | $25.3M | $36.7M | $37.5M |
| Pretax income | $27.7M | $246M | $253M |
| Income tax | $12.5M | $53.2M | $37.7M |
| Net income | $15.3M | $192M | $216M |
| Net income to common | $15.3M | $192M | $216M |
| Diluted EPS | $0.18 | $2.26 | $2.27 |
| Diluted shares | 0.08B | 0.09B | 0.10B |
| Cash flow | |||
| Cash from operations | $112M | $269M | $318M |
| Capital expenditure | $0.4M | $2.4M | $4.8M |
| Free cash flow | $111M | $266M | $313M |
| Depreciation and amortization | $12.3M | $11.3M | $13.0M |
| Stock-based compensation | $66.1M | $27.2M | $16.1M |
| Balance sheet | |||
| Cash and short-term investments | $388M | $575M | $1.1B |
| Current assets | — | $1.1B | $1.7B |
| Current liabilities | — | $306M | $343M |
| Property and equipment, net | — | $5.0M | $7.4M |
| Total assets | — | $1.2B | $1.8B |
| Total liabilities | — | −$13.1B | −$14.3B |
| Shareholders' equity | $598M | $14.3B | $16.1B |
| Margins | |||
| Gross margin | 0.7% | 1.9% | 1.8% |
| Net margin | 0.4% | 1.5% | 1.6% |
| FCF margin | 2.9% | 2.1% | 2.3% |
| Returns | |||
| Return on equity | 2.6% | 2.6% | 1.4% |
| Return on assets | — | 16.1% | 14.5% |
| Return on tangible equity | 2.6% | 1.3% | 1.3% |
| Growth | |||
| Revenue growth | — | 225.3% | 9.5% |
| Net income growth | — | 1,160.8% | 12.1% |
| EPS growth | — | 1,155.6% | 0.4% |
| FCF growth | — | 138.9% | 17.7% |
| Share count change | — | 3.0% | 11.5% |
| Financial health | |||
| Current ratio | — | 3.5x | 4.9x |
| Quick ratio | — | 3.5x | 4.9x |
| Capital allocation | |||
| Capex / revenue | 0.0% | 0.0% | 0.0% |
| Stock comp / revenue | 1.7% | 0.2% | 0.1% |
| Quality scores | |||
| Piotroski F-score | — | — | 4.0 |
| Accruals ratio | — | −6.4% | −6.9% |
Source: SEC EDGAR XBRL filings (CIK 0001493318). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.